All In Biotech

Drug Trial Radar · NCT07467993

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

A Phase 2a, Randomized, Participant- and Investigator- Blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With DSM-5 Schizophrenia (STAR-1)

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

142

Planned (sponsor's estimate)

Start

Mar 16, 2026

Primary completion

Jul 29, 2027

Study completion Jul 29, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

Conditions

  • Schizophrenia

Interventions

  • GXV813Drug

    GXV813 administered orally.

  • PlaceboDrug

    Placebo administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Positive and Negative Symptom Scale (PANSS) total scoreTime frame: Baseline, Week 6

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Pillar Clinical Research LLC

    Bentonville, Arkansas · Recruiting

  • CNRI Los Angeles LLC

    Pico Rivera, California · Recruiting

  • Segal Institute for Clinical Research

    Miami, Florida · Recruiting

  • CenExel iResearch

    Decatur, Georgia · Recruiting

  • Uptown Research Institute LLC

    Chicago, Illinois · Recruiting

  • Pillar Clinical Research LLC

    Chicago, Illinois · Recruiting

  • Arch Clinical Trials LLC

    St Louis, Missouri · Recruiting

  • Novartis Investigative Site

    Haskovo, Bulgaria · Recruiting

  • Novartis Investigative Site

    Kazanlak, Bulgaria · Recruiting

  • Novartis Investigative Site

    Lovech, Bulgaria · Recruiting

  • Novartis Investigative Site

    Plovdiv, Bulgaria · Recruiting

  • Novartis Investigative Site

    Sliven, Bulgaria · Recruiting

  • Novartis Investigative Site

    Sofia, Bulgaria · Recruiting

  • Novartis Investigative Site

    Veliko Tarnovo, Bulgaria · Recruiting

  • Novartis Investigative Site

    Vratsa, Bulgaria · Recruiting

  • Novartis Investigative Site

    Sofia, BGR, Bulgaria · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.